icon-folder.gif   Conference Reports for NATAP  
 
  EASL 46th Annual Meeting
March 30th - April 3rd 2011
Berlin, Germany
Back grey_arrow_rt.gif
 
 
 
Boceprevir at EASL
 
 
  From Jules: There were a bunch of studies on bocprevir at EASL including on IL28B, anemia, lead-in, resistance, adherence, overall safety, response-guided therapy, and the publication of their data came out during EASL in NEJM.
 
Simplified Explanation of the Phase 3 Studies of HCV Protease Inhibitor Boceprevir - (03/21/11)
 
NEJM: Boceprevir for Untreated Chronic HCV Genotype 1 Infection - (03/31/11)
 
NEJM: Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection - (03/31/11)
 
EASL: New Data Analyses with VICTRELIS (boceprevir), Merck's Investigational Medicine, Examined Possible Predictors of Sustained Virologic Response - (04/01/11) Merck press release
 
EASL: VICTRELIS (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control - (04/01/11) Merck press release
 
EASL: Boceprevir in Addition to Standard of Care Enhanced SVR in Hepatitis C Virus Genotype-1 With Advanced Fibrosis/Cirrhosis: Subgroup Analysis of SPRINT-2 and RESPOND-2 Studies - (04/01/11)
 
EASL: IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR COMBINATION THERAPY - (04/01/11)
 
EASL: Adherence To Assigned Dosing Regimen and Sustained Virologic Response Among Hepatitis C-Genotype 1 Previously Untreated and Peginterferon/Ribavirin Treatment-Failure Patients Treated With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin (patients with >80% adherence to all dosing achieved 90% cure rates. My guess is if adherence is 100% SVR rates will be higher) - (04/05/11)
 
EASL: Overall Safety Profile of Boceprevir Plus Peginterferon Alfa-2b/Ribavirin - (04/12/11)
 
EASL: Response-Guided Therapy With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin Reduces Treatment Duration in Previously Untreated and Previous-Treatment-Failure Patients With HCV Genotype 1 - (04/12/11)
 
EASL: Anemia During Treatment With Peginterferon Alfa-2b/Ribavirin With or Without Boceprevir is Associated With Higher SVR Rates: Analysis of Previously Untreated and Previous Treatment-Failure Patients - (04/12/11)
 
EASL: Frequencies of Resistance-Associated Amino Acid Variants Detected by 454 Sequencing During Combination Treatment With Boceprevir Plus Pegintron (Peginterferon Alfa-2b)/Ribavirin in HCV (GT1)-Infected Subjects - (04/12/11)
 
EASL: Sustained Virologic Response and Boceprevir Resistance-Associated Variants Observed in Patients Infected With HCV Genotype 1a/1b When Treated With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin: SVR rates among patients with G1b virus were consistently higher compared with G1a patients in both SPRINT-2 and RESPOND-2 - (04/12/11)
 
EASL: The New England Journal of Medicine (NEJM) Publishes Pivotal Studies Showing Merck's Investigational Medicine VICTRELIS (boceprevir) in Combination Therapy Significantly Increased SVR In Patients with Chronic HCV Genotype 1 Who Failed Previous Treatment or Who Were New to Treatment Compared to Control - (04/01/11) Merck press release
 
EASL: BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN - (04/03/11)
 
EASL: Sustained Virologic Response and Boceprevir Resistance-Associated Variants Observed in Patients Infected With HCV Genotype 1a/1b When Treated With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin: SVR rates among patients with G1b virus were consistently higher compared with G1a patients in both SPRINT-2 and RESPOND-2 - (04/12/11)